Report error Found 9 Enz. Inhib. hit(s) with all data for entry = 12877
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 13nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 131nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 532nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 875nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 878nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 957nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 959nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 1.62E+3nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics
US Patent
Nerio Therapeutics
US Patent
Affinity DataIC50: 3.00E+4nMAssay Description:Compound activity was determined in an in vitro enzymatic assay using untagged, full-length human PTPN2 (TC45) (1-387) protein. PTPN2 was produced in...More data for this Ligand-Target Pair
